6059-29-6

Usage

Uses

Used in Pharmaceutical Industry:
[3-[(Benzyl)oxy]-2-pyridinyl]methanol is used as a key intermediate in the synthesis of various pharmaceuticals due to its unique structural features, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
[3-[(Benzyl)oxy]-2-pyridinyl]methanol is also utilized as a building block in the production of agrochemicals, playing a crucial role in the synthesis of effective pesticides and other agricultural chemicals to enhance crop protection and yield.
Used in Medicinal Chemistry:
[3-[(Benzyl)oxy]-2-pyridinyl]methanol serves as a valuable component in medicinal chemistry, where its structural attributes can be exploited to design and develop novel molecules with potential therapeutic properties.
Used in Drug Development:
Its potential applications in drug development are attributed to the compound's structural features, which can be harnessed to create new drug candidates with improved pharmacological profiles.
Safety Note:
It is essential to handle [3-[(Benzyl)oxy]-2-pyridinyl]methanol with care and adhere to proper safety protocols when working with it in a laboratory setting to ensure the safety of researchers and the integrity of experiments.

InChI:InChI=1/C13H13NO2/c15-9-12-13(7-4-8-14-12)16-10-11-5-2-1-3-6-11/h1-8,15H,9-10H2

Upstream product

• 100-39-0 benzyl bromide 
• 14173-30-9 3-hydroxy-2-hydroxymethylpyridine hydrochloride 
• 1121-25-1 2-methyl-3-pyridinol 
• 177559-01-2 3-(benzyloxy)-2-methylpyridine 
• 14047-53-1 3-hydroxy-2-hydroxymethylpyridine 
• 100-44-7 benzyl chloride 

Downstream Products

• 94454-57-6 3-(phenylmethoxy)-2-pyridinecarboxaldehyde 
• 1438073-62-1 N-(3-chloro-4-fluorophenyl)-6-(3-(hexahydro-2H-pyrano[3,2-b]pyridin-5(3H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 70381-92-9 2,3-dihydro-4H-pyrano<3,2-b>pyridine 
• 70381-91-8 2-(3-hydroxypropyl)pyridin-3-ol 
• 944445-41-4 3-(benzyloxy)-2-(chloromethyl)pyridine 
• 136423-93-3 (3-benzyloxy)-2-pyridinecarboxaldehyde guanylhydrazone sulphate 
• 647840-33-3 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(3-benzyloxy-2-pyridyl)-3-(tert-butoxycarbonylamino)-2-triisopropylsilyloxypropionate 
• 647840-35-5 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-(morpholino)ethylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(3-benzyloxy-2-pyridyl)-3-(tert-butoxycarbonylamino)-2-hydroxypropionate 
• 139745-90-7 (E)-ethyl 3-(3-(benzyloxy)-2-pyridinyl)propenoate 
• 839711-82-9 (E)-ethyl 3-(3-(benzyloxy)-N-oxypyridin-2-yl)acrylate 

Relevant academic research and scientific papers

Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation

Gd-based MRI contrast agents (GBCAs) have come under intense regulatory scrutiny due to concerns of Gd retention and delayed toxicity. Three GBCAs comprising acyclic Gd chelates, the class of GBCA most prone to Gd release, are no longer marketed in Europe

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter-and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS

The present invention is directed to novel pyrido[4,3-d]pyrimidin-4(3H)-one derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variables R1, R2, R3, R4 and R5 are as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.

Stereoselective synthesis of swainsonines from pyridines

An efficient synthesis of (-)-swainsonine and (-)-2,8a-di-epi-swainsonine was developed starting from readily available 2-pyridinecarbaldehyde and 3-hydroxypyridine. In particular, it was demonstrated that the mixture of simple indolizidines, i.e. lentigi

New highly active taxoids from 9β-dihydrobaccatin-9,10-acetals. Part 4

It was shown that a new taxane analogue 3, which exhibited both in vitro antitumor activity and in vivo efficacy by both iv and po administration, was prone to be metabolized by human liver microsomes. We identified a major metabolite, M-1, generated by h

ORTHO SUBSTITUTED AROMATIC COMPOUNDS USEFUL AS ANTAGONISTS OF THE PAIN ENHANCING EFFECTS OF E-TYPE PROSTAGLANDINS

The invention relates to compounds of the formula (I): STR1 wherein A, B and D are various ring systems such as phenyl, R. sup.1 includes carboxy, R 3 is hydrogen or C 1-4 alkyl and Z is a linking group such as--(CH(R 5)) m--wherein m is 2, 3 or 4, and R 5 includes hydrogen and methyl; and pharmaceutically acceptable salts and in vivo hydrolysable esters or amides thereof, processes for preparing these compounds, pharmaceutical compositions comprising them, and their use in the treatment of pain.

Guanylhydrazones of 3-substituted 2-pyridinecarboxaldehyde and of (2-substituted 3-pyridinyloxy) acetaldehyde as prostanoid biosynthesis and platelet aggregation inhibitors

Some guanylhydrazones of (3-benzyloxy)-2-pyridinecarboxaldehyde and of (2-substituted 3-pyridinyloxy)acetaldehyde were prepared in order to evaluate their possible activity as inhibitors of prostanoid biosynthesis in human serum.Only those products of the second group without the carboxylic function reduced prostanoid generation in vitro at the highest concentration; they also inhibited platelet aggregation induced by arachidonic acid and U-46619.The results suggest that these compounds are both inhibitors of cyclooxygenase and cyclic endoperoxides/TxA2 platelet receptor antagonists.

Dihydropyridines and their use in the treatment of asthma

New dihydropyridines are described. These compounds are useful in the treatment of asthma.